title: CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
abstract: Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations. Cancer Discov; 6(7); 697-9. ©2016 AACRSee related article by Patnaik et al., p. 740.
authors.affiliation: The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.
authors.forename: Joline S J
authors.initials: JS
authors.lastname: Lim
authors.affiliation: The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.
authors.forename: Nicholas C
authors.initials: NC
authors.lastname: Turner
authors.affiliation: The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom. timothy.yap@icr.ac.uk.
authors.forename: Timothy A
authors.initials: TA
authors.lastname: Yap
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D051358:Cyclin-Dependent Kinase 4 / Q000037:antagonists & inhibitors*; D051361:Cyclin-Dependent Kinase 6 / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D001562:Benzimidazoles; C000590451:abemaciclib; D051358:Cyclin-Dependent Kinase 4; D051361:Cyclin-Dependent Kinase 6